Effects of Apatinib mesylate combined with FOLFIRI chemotherapy in treatment of patients with advanced colorectal cancer
Objective:To observe effects of Apatinib mesylate combined with FOLFIRI chemotherapy in treatment of patients with advanced colorectal cancer.Methods:The clinical data of 86 patients with advanced colorectal cancer admitted to this hospital from March 2021 to March 2022 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,43 cases in each group.The control group was treated with FOLFIRI chemotherapy regimen,while the observation group was treated with Apatinib mesylate on the basis of that of the control group.Both groups were treated for 12 weeks.The clinical efficacy,the levels of tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 19-9(CA19-9)]and angiogenesis indexes[vascular endothelial growth factor(VEGF),microvessel density(MVD)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate(DCR)of the observation group was 95.35%(41/43),which was higher than 72.09%(31/43)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CEA,CA19-9 and CA125 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of VEGF and MVD in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as gastrointestinal reaction,bone marrow suppression,liver function damage,hand-foot syndrome and cardiac toxicity between the two groups(P>0.05).Conclusions:Apatinib mesylate combined with FOLFIRI chemotherapy in the treatment of the patients with advanced colorectal cancer can improve DCR,and reduce the levels of tumor markers and angiogenesis indexes.Moreover,it is superior to single FOLFIRI chemotherapy.
NETL
NSTL
万方数据
